Outcome analysis of application of recombinant human thyrotropin alpha for exogenous stimulation TSH in patients with differential thyroid cancer based on literature and own experience
Differentiated thyroid cancer (DTC) is the mostfrequently occurring endocrine cancer. A necessary conditionfor radioiodine treatment and follow up patients (thyroglobulin determination) is hypothyroidism. Acute hypothyroidism may be induced by thyroid hormone withdrawal or introduction of recombinant human TSH (rhTSH). The results of treatment with recombinant human thyrotropin alfa was evaluated in the literature and our clinical experience (10patients). Using of «Tirogen» significantly improves the quality of life for patients with DTC, stimulates the uptake of radioiodine, which allows to achieve a complete cure of patients with fewer active 131I. Use of the drug «Tirogen» significantly improves the quality of life of patients with DTC, low-dose radioiodine plus thyrotropin alfa was as effective as high dose radioiodine. Using of «Tirogen» in cases of thyroid cancer Radioiodine resistance of patients with low levels of TSH and patients with bilateral vocal fold paresis (without imposing taheostomy) is the method of choice and the only way to complete recovery of patients with DTC: